• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

Pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease

    Keerti S Patil(K B Kulkarni), A. V. Dawari, Abhijeet Muglikar, Sachin Bhavthankar

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 4123-4128

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Chronic Renal Disease is a fast-growing disease worldwide achieving the endemic levels. The use of NSAIDs has been associated with renal function deterioration through variable mechanisms. Present study was aimed at pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease at a tertiary hospital. Material and Methods: Present study was retrospective, case record-based analysis conducted in case records of patients admitted & diagnosed as nonsteroidal anti-inflammatory drugs-(NSAID) induced chronic kidney disease. Results: In present study, 48 case records evaluated. Majority patients were from 51-60 years (37.5 %) & 41-50 years age group (27.08 %), were male (68.75 %) & labourer by occupation (52.08 %). Common co-morbidities noted were hypertension (77.08 %), bone and joint disease (33.33 %), diabetes (31.25 %), cardiovascular disease (29.17 %) & malignancy (4.17 %). Among 48 patients, common CKD stage was Stage 3a (39.58 %) followed by Stage 3b (29.17 %), Stage 2 (22.92 %) & Stage 4 (8.33 %). Treatment receiving were Hemodialysis (54.17 %), Only medicine (22.92 %), Peritoneal dialysis (10.42 %) & Kidney transplantation (12.5 %), Common NSAIDs used was Diclofenac/Aceclofenac (45.83 %), Paracetamol (39.58 %), Ibuprofen (27.08 %), Ketorolac (4.17 %) & Nimesulide (4.17 %). Oral Route of administration was common (77.08 %). Though majority of patients using 1 NSAID (47.92 %) followed by 2 NSAIDs use (35.42 %), ≥3 NSAIDs use (16.67 %). Common purpose of use was headache (60.42 %), generalized pain (45.83 %), joint pain (33.33 %), dental pain (14.58 %), menstrual pain (12.50 %) & renal colic (8.33 %). Conclusion: Non-steroidal anti-inflammatory drug induced nephrotoxicity should be considered as significant adverse effect. Physicians & general practitioners should discourage on the counter use of NSAIDs.
Keywords:
    chronic kidney disease nonsteroidal anti-inflammatory drugs pharmacovigilance Paracetamol diclofenac
  • PDF (200 K)
  • XML
(2022). Pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease. European Journal of Molecular & Clinical Medicine, 9(4), 4123-4128.
Keerti S Patil(K B Kulkarni), A. V. Dawari, Abhijeet Muglikar, Sachin Bhavthankar. "Pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 4123-4128.
(2022). 'Pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease', European Journal of Molecular & Clinical Medicine, 9(4), pp. 4123-4128.
Pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 4123-4128.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 5
  • PDF Download: 21
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus